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The use of 99mTc-MIBI scanning in multiple myeloma
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Summary Tc-99m 2 methoxy-isobutyl-isonitrile (9SmTc-MIBI), also called Sestamibi, is a safe and effective
scanning agent in solid tumours. Its use in imaging lesions in multiple myeloma has been studied in 21 patients
with either multiple myeloma (19/21) or monoclonal gammopathy of undetermined significance (MGUS) (2/
21). 99mTc-MIBI scanning was positive in 14 patients, 13 with active myeloma and one patient with MGUS
showing possible transformation to a more accelerated phase. In seven patients 99mTc-MIBI scanning was
negative. In four of them, the result was unexpected, as they had the features of active myeloma. All four were
either primarily or secondarily resistant to chemotherapy, with high total cumulative doses of doxorubicin.
Overexpression of P-glycoprotein associated with multidrug resistance could be a factor, as it has been shown
that 99'Tc-MIBI is actively eliminated from the cell by P-glycoprotein. With this assumption, sensitivity of the
scanning technique in this series is 100%, and the specificity 88%. No toxicity was experienced by any patient.
99mTc-MIBI scanning is a useful adjunct to the investigation of multiple myeloma, and may have potential as
an in vivo test for multidrug resistance.
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Technetium-99m 2 methoxy-isobutyl-isonitrile (99mTc-MIBI)
is a tracer with gamma emission characteristics that was
introduced in 1984 as an alternative to TI-201 for the study
of myocardial perfusion. The agent gave satisfactory results
and was well tolerated (Wackers et al., 1989). Clinical
observations and laboratory information on the mechanism
of uptake of 99mTc-MIBI led to new proposals for its use in
cancer patients.
In 1987, uptake of 99mTc-MIBI by pulmonary metastases
of thyroid cancer was described by Muller et al. (1987); since
then, it has been studied in bronchial carcinomas (Muller et
al., 1989), osteosarcomas (Hassan et al., 1989), brain tumours
(Albuquerque et al., 1992), tumours of the nasopharynx (Kao
et al., 1993), breast cancer (Khalkhali et al., 1994),
parathyroid adenomas (Coakley et al., 1989) and lymphomas
(Kostakoglu et al., 1992).
In 1994, Durie et al. first showed the increased uptake of
99mTc-MIBI by bone lesions in patients with active multiple
myeloma (MM). Those preliminary data were encouraging,
and were confirmed by Malpas et al. and Unlu et al. in 1995. A
potential advantage of 9'Tc-MIBI scan in predicting multi-
drug resistance (MDR) has been suggested by some authors
(Ballinger et al., 1995), since there is both in vivo and in vitro
evidence that P-glycoprotein (which has been associated with
MDR) is responsible for the elimination of MIBI from several
types ofmalignant cells. There have been no clinical studies in
myeloma patients to verify the assumption.
The role of 99mTc-MIBI in the detection of MM in bone
marrow has been examined with regard to reliability,
sensitivity and toxicity, and compared with radiography as
the standard reliable imaging technique. The potential use of
99mTc-MIBI in the management of the disease, as a predictor
of MDR, is discussed.
Patients, materials and methods
Twenty-one (21) patients of a median age of 62 years, with
multiple myeloma (MM) (19/21) or monoclonal gammo-
pathy of undetermined significance (MGUS) (2/21) were
examined with technetium-99m-2-methoxy-isobutyl isonitrile
(99mTc-MIBI) scan, and the results were correlated with
clinical, biochemical and radiological information on each
patient.
A dose of 450 MBq of 99mTc-MIBI was administered to
each patient. After reviewing 10 min, 1, 4 and 24 h planar
images, those done at 1 and 4 h after injection were obtained
and evaluated in each patient. A Siemens Orbiter 75 gamma
camera equipped with a low-energy, general purpose parallel-
hole collimator linked to a Micas V computer (Park Medical)
was used. Pulse height analysis was carried out with a 15%
window on the peak energy of 140 keV for 99mTc-MIBI. A
posterior view of the pelvis was done for 600 000counts; the
other spot views, anteriorly and posteriorly of the body, were
acquired with the same preset time. Physiological uptake of
99mTc-MIBI was seen in the heart, thyroid and salivary
glands, spleen, kidneys, bladder, lungs, skeletal muscle, liver,
gall bladder, biliary system and both small and large
intestines.
Criteria of assessment
All examinations were carried out by two nuclear medicine
physicians who were unaware of the radiological findings.
Results were considered concordant if the detected area of
abnormal uptake of99mTc-MIBI matched the osteolytic lesion
detected on skeletal survey.
In 2/21 patients magnetic resonance imaging (MRI)
scanning was considered necessary to determine the anatomy
of the lesion.
The patients were clinically and biochemically examined
when the 99mTc-MIBI and skeletal survey were performed, in
order to determine their clinical status (active disease,
remission or plateau phase).
Haematological and biochemical examination included a
full blood count, liver and renal function tests, serum
immunoglobulin levels, protein electrophoresis, C-reactive
protein, and urine light chain excretion.
Information relating to the date of onset of the disease,
previous treatment (particularly the cumulative total dose of
anthracycline given), response to treatment, possible recur-
rences and their management was noted, so that active
disease which was apparently resistant to chemotherapy
could be identified.
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Calculation of sensitivity and specificity of 99mTc-MIBI
scanning results was as follows:
True positives
True positives + false negatives
True negatives
True negatives + false positives
Results
Twenty-one (21) patients with a median age of 62 years
(range 33 - 81 years), with either multiple myeloma (MM)
(19/21) or monoclonal gammopathy of undetermined
significance (MGUS) (2/21) were investigated by 99mTc-MIBI
scanning. Fourteen patients (67%) showed increased uptake
at 1 and 4 h after the injection (Figures la, b, 2 and 3), while
seven (33%) were negative at 4 h (Figure 4). One of these (1/
7) showed slightly increased uptake only I h after injection.
Figures 1 - 5 are 4 h images.
Figure 2 Active myeloma (patient PJ). 99mTc-MIBI images of the
posterior thoracic spine. Extensive bone marrow uptake in the
thoracic vertebrae, all the ribs and scapulae is seen, so that the
image almost looks like a bone scan. Normal uptake is seen in the
heart, liver, spleen and gut inferiorly.
Figure I Active myeloma (patient MB). (a) 99mTc-MIBI study
(posterior view of pelvis) showing increased uptake in the
sacroiliac regions, ischia and proximal femora. (b) 99mTc-MIBI
study of the thighs (anterior view). Increased uptake of 99mTc-
MIBI is seen linearly in the bone marrow with the negative
parallel lines of cortical uptake between the muscles of the thighs,
which show normal uptake.
Figure 3 Active myeloma (Patient GH). 99mTc-MIBI study
(anterior view of knees) shows mainly symmetrical uptake in
the marrow of the distal femora and tibial condyles.The 14 patients with positive results were examined to see
how effective 99mTc-MIBI scanning was in detecting active
disease in bones, and whether clinical, biochemical and
radiological information corresponded with 99mTc-MIBI
scanning.
Twelve of the 14 patients with increased uptake had active
myeloma confirmed both clinically and biochemically; one
was deemed to have indolent MM with an increased 'M'
band and bone marrow involvement, but no symptomatol-
ogy, and a negative skeletal survey. There was enough
evidence to suggest that the patients studied had bone
marrow involvement, and therefore the results of the 99mTc-
MIBI scan in these 13 cases (93%) were characterised as true
positive (TP) (Table I).
Skeletal survey or MRI scanning indicated bony involve-
ment in 11/14 patients (78%) who had positive 99mTc-MIBI
scans. All these patients were diagnosed as having active
disease; three of them were newly diagnosed and therefore
previously untreated (Tables I and II). The results of 99mTc-
MIBI scanning relating to the localisation of bone lesions
were almost or completely concordant with those of skeletal
survey in 6/11 (54%) patients. There was, however, partial
concordance in the results of the remaining five (Table II,
Figure 5a and b).
The 99mTc-MIBI scan was positive in one patient with
MGUS (1/14; 7%). This has to be considered as a false-
positive result (Table I).
Figure 4 Negative 99mTc-MIBI study (posterior view of chest)
(patient IF). There are physiological accumulations in the heart,
gall bladder and gastrointestinal tract. There is an enlarged left
kidney. Note the absence of bone marrow uptake in the spine.
99mTc-MIBI in myeloma
EB Tirovola et al
1817
The results of the 7/21 (33%) patients in whom 99mTc-
MIBI scanning was negative (6/7) or showed transient uptake
at 1 h (1/7) included four (60%) false negatives (FN) (Table
I). One of these patients (IF) had a history of primary
resistance to therapy, and the other three had received large
cumulative doses of anthracycline, which could have
contributed to their multidrug resistance (MDR) (Table III)
and would be likely, therefore, to cause a negative 99mTc-
MIBI scan.
In the 3/7 (43%) cases with negative 99mTc-MIBI scans, the
results were as expected (true negatives), since one patient
was diagnosed as having MGUS and the remaining two
patients were in remission (Table I).
The sensitivity and specificity of 99mTc-MIBI scanning in
MM patients, estimated according to the above results, were
found to be 82% and 75% respectively. These figures would
significantly increase (the sensitivity to 100% and the
specificity to 88%) if the negative results from the MDR
cases were considered as true.
Discussion
Various bone-seeking radiopharmaceutical agents have been
used in multiple myeloma, the commonest being technetium-
99m methylene diphosphate (Wahner et al., 1980). It has
been shown that conventional radionuclide bone imaging is
less sensitive at detecting skeletal lesions than conventional
radiography. Conventional radiography will detect individual
lesions in 75-95% of cases, while the equivalent sensitivities
for radionuclide bone imaging range from 40% to 60%
(Feggi et al., 1988). Myeloma generally produces a poor
osteoblastic response and, therefore, radiopharmaceutical
agents, such as technetium-99m-labelled diphosphonate, are
poorly taken up.
At present, the most reliable method of detecting bone
disease in MM is radiography, with about 80% sensitivity
(Waxman et al., 1981). However, the lesions shown on the
radiographic films do not always signify active disease, but
may represent lesions already healed. In addition, radio-
graphy is not able to detect areas of disease in the bone
marrow.
In this pilot study, 99mTc-MIBI has produced results
comparable with radiography. Images at 10 min showed
high blood pool activity. Uptake of MIBI was clearly seen at
1 h and contrast increased at 4 h. Fading of uptake at 24 h
was noted in some patients. 99mTc-MIBI is well tolerated and
does not have any toxic effects. There is good concordance
between the findings of the 99'Tc-MIBI scan and the skeletal
survey in those patients with active disease. There are some
patients with partially concordant results (Table II), Where
lesions shown on skeletal survey do not always correspond to
the positive areas ofthe 99mTc-MIBI scan, and vice versa. The
mechanism of uptake of 99mTc-MIBI could help to explain
these results.
The main mechanism of cellular uptake of99mTc-MIBI has
been shown to involve passive distribution across the plasma
cell and mitochondrial membranes in tissues that maintain
negative plasma membrane potentials or are rich in
mitochondrial content, i.e. myocardial, renal or hepatic cells
Table I Clinical, biochemical and radiological findings in 21 patients with either positive or negative 99mTc-MIBI scan
Symptoms (+) Biochemistry (+) Skeletal survey (+) MDR (+ )
99mTc-MIBI (+) 14 TP13 12/13 active MM 13/13 12 active MM 11/13 active MM 0
1 indolent MM
FPI 0 1/1 MGUS 0 0
99mTc-MIBI (-) 7 TN3 0 2/3 1/3 plateau phase 1/3 plateau phase 0
1/3 MGUS
FN4 4/4 4/4 4/4 4
MM, multiple myeloma; MDR, multidrug resistance; TP, true positive; FP, false positive; TN, true negative; FN, false negative.A-: 99mTc-MIBI in myeloma
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(Piwnica-Worms et al., 1990). However, alterations in cell
metabolism, which occur in malignant cells, can affect the
membrane potential, which can then influence the accumula-
tion of "mTc-MIBI within the cell (Chen, 1988). Thus, 99mTc-
MIBI could sequester in abnormal plasma cells and, as a
result, disease can be detected in the bone marrow, while
Table II Sites of disease revealed in the skeletal survey and on 99'Tc-MIBI scanning in 11 patients with active multiple myeloma and evidence
of disease on both imaging tests
Patient
Completely concordant
99mTc-MIBI-SS
Symptoms
JP Mid-thoracic back
pain
JD Back pain
PW Back pain
Almost concordant RJ Back pain
GH Weight loss, back
pain
JW Weight loss, back
pain
SG Widespread bone
pain
MB Right-sided chest
pain, weight loss,
anaemia
Partially concordant GT Back, left shoulder
pain
PJ Back and right
shoulder pain,
leg weakness
DL Renal impairment,
confusion,
anaemia
Skeletal survey (SS)
Thoracic, lumbar
spine, sacrum,
pelvis
T7 - 10, L ilium,
skull
Multiple lesions in
spine, pelvis
Thoracic spine (TH)
lumbar spine
Thoracic spine
(T8 -10) R femur
sacrum
Thoracic spine
Femora, thoracic
and lumbar spine,
scapula, clavicle
Pelvis, left femur,
humeri, skull,
ribs
Thoracic spine,
pelvis, humeri
L2, L4, right
humerus
Left scapula,
right humerus,
lumbar spine,
skull
Thoracic, lumbar
spine, sacrum,
pelvis
T7, TIO, sternum
Multiple lesions in
spine and sternum
Thoracic spine, pelvis,
sternum, R anterior
chest
Several sites in spine
(TS, sacrum
included), femora,
tibia, sternum, skull
Thoracic spine,
scapula
Femora, mandible,
tibia, shafts, knees,
sternum, ribs
(spine negative)
Pelvis, femora,
humeri, ribs,
widespread spinal
lesions, scapula
Thoracic spine, left
scapula, rib 3 right
Widespread lesions in
spine, humeri, ribs,
pelvis, sternum,
scapula, femora
Scapula, femur, pelvis
a
Figure 5 Active myeloma (patient RJ). (a) 99mTc-MIBI study (posterior view of upper abdomen). There is abnormal accumulation of 99mTc-
MIBI in the marrow of the lower thoracic spine. No uptake seen in the lumbar spine as this had recently been treated with radiotherapy. (b)
MRI of the spine. Multiple areas of involvement of the marrow owing to myeloma are seen in the sagittal sections of the thoracolumbar
spine.
99mTc-MIBI scan Previously treated (YIN)
y
y
y
y
y
N
y
N
y
y
N99mTc-MIBI in myeloma
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Table Ill Clinical, biochemical and radiological characteristics of patients with primary or multidrug resistance (MDR)
Urine light chain
Patient Symptoms excretion (g24h-') Skeletal survey (SS) 99mTC-MIBI Onset/treatment
AW Back pain 1.9 C5, T5, L5, pelvis Increased uptake in 1991/VAMP 1994/
humeri, femora T/L spine, but Interferon prednisolone
transient -+PD
IF Back pain 2 Right femur, skull Negative 1994/Melphalan and
T7, L2, right prednisolone. No
humerus response
AH Back pain 3.6 Vertebral column Negative 1994.on C-VAMP
medulla (plasma when 99mTc-MIBI
cytoma), pelvis performed
AP Pain in left humerus 2.4 Ribs, shoulders, Negative 1994/C-VAMP. No
and lower ribs C5-7, T9- 10,. response
skull
C-VAMP, cyclophosphamide (C), vincristine (V), doxorubicin (A), methyl-prednisolone (MP); PD, progressive disease.
radiography is unable to reveal abnormalities of constituents
of the marrow. Furthermore, healed lesions which might
appear on the radiographic films or MRI scans of previously
treated patients do not show increased uptake on 99mTc-MIBI
scanning (Figure 5a and b). It is, however, interesting that
there are abnormal areas on skeletal survey that do not
appear positive on 99mTc-MIBI scanning in previously
untreated patients. These may represent areas of drug
resistance, since there is both in vivo and in vitro evidence
that P-glycoprotein (which is associated with drug resistance
in MM) is responsible for the elimination of 99mTc-MIBI
from malignant cells (Ballinger et al., 1995).
The potential application of 99mTc-MIBI scanning in the
functional detection of drug resistance, either before
chemotherapy in various tumours known to be primarily
resistant, or during chemotherapy to monitor acquired drug
resistance has been explored (Moretti et al., 1995a, b). It has
been shown that99'Tc-MIBI is atransport substrate recognised
by the human MDR1 P-glycoprotein (P-gp), which recognises
and transports out of the cell a large group of cytotoxic
compounds having little or no structural or functional
similarities other than being relatively small, hydrophobic
and cationic (i.e. anthracyclines) (Pearce et al., 1989). 99mTc-
MIBI also fulfils these requirements. In vitro studies have
confirmed that it can be transported by P-gp (Piwnica-Worms
etal., 1993). Ithas also beenimmunohistochemically confirmed
that P-gp expression is associated with MDR in myeloma cells
(Dalton etal., 1989). Thefourcasesin ourstudyinwhich9"Tc-
MIBI scanning was negative or showed slightly increased
uptake only at 1 h after injection, despite the activity of the
disease, could be explained by 99mTc-MIBI elimination of
myeloma cells as a result ofMDRl P-gp overexpression, since
the clinical histories indicated either primary or acquired drug
resistance. Immunohistochemical detection andquantitation of
P-gp in suspicious areas showing no uptake of 99mTc-MIBI
would help to confirm the overexpression of P-gp and its
relation to 99mTc-MIBI negativity, and these studies are in
progress.
If the drug-resistant cases are accepted as true-negative
results, then the sensitivity and specificity of 99mTc-MIBI
scanning increase considerably, from 82% to 100%, and from
75% to 88% respectively.
The unexpected positive scan in one patient with MGUS
raises the question whether 99mTc-MIBI scanning could detect
progression of MGUS to MM earlier than any other imaging
procedure; this is a matter for further research.
In conclusion, this pilot study shows that 99mTc-MIBI
scanning is a useful addition to the investigation process for
MM, and in the management of patients with plasma cell
disorders.
References
ALBUQUERQUE L, BAILLET G, DELATTRE J, CHEN Q AND
POISSON M. (1992). Tomoscintigraphie cerebrale au MIBI dans
la surveillance des tumeurs gliales de l'adulte. J. Med. Nucl.
Biophys., 16, 181.
BALLINGER JR, HUA HA, BERRY BW, FIRBY P AND BOXEN I.
(1995). 99mTc sestamibi as an agent for imaging P-glycoprotein-
mediated multi-drug resistance: in vitro and in vivo studies in a rat
breast tumour cell line and its doxorubicin-resistant variant. Nucl.
Med. Commun., 16, 253 - 257.
CHEN LB. (1988). Mitochondrial membrane potential in living cells.
Annu. Rev. Cell Biol., 4, 155 - 181.
COAKLEY AJ, KETTLE A, WELLS CP, O'DOHERTY MJ AND
COLLINS R. (1989). Technetium-99m sestamibi: a new agent for
parathyroid imaging. Nucl. Med. Commun., 10, 791 - 794.
DALTON WS, GROGAN TM, RYBSKI JA, SCHEPER RJ, RICHTER L,
KAILEY J, BROXTERMAN HJ, PINEDO HM AND SALMON SE.
(1989). Immunohistochemical detection and quantitation of P-
glycoprotein in multidrug resistant human myeloma cells:
association with level of drug resistance and drug accumulation.
Blood, 73, 747 - 752.
DURIE BGM, WAXMAN A, JOCHELSON M, GILES FJ, HAMBURG S
AND AVEDON M. (1994). Technetium-99m-MIBI scanning in
multiple myeloma (MM) (abstract). Proc. Am. Soc. Clin. Oncol.,
13,411.
FEGGI LM, SPANEDDA R, SCUTELLARI PN, PRANDINI N,
GENNARI M AND ORZINCOLO C. (1988). Bone marrow
scintigraphy in multiple myeloma: a comparison with bond
scintigraphy and skeletal radiology. Radiologica Medica, 76,
311 - 315.
HASSAN I, SAHWEIL A, CONSTANTINIDES C, MAHMOUD A, NAIR
M ANDABDEL-DAYEM H. (1989). Uptake and kinetics ofTc-99m
hexakis 2-methoxy isobutyl-isonitrile in benign and malignant
lesions in the lungs. Clin. Nucl. Med., 14, 333 - 340.
KAO C, WANG S, LIN W, HSU C, LIAO S AND YEH S. (1993).
Detection of nasopharyngeal carcinoma using Tc-99m methox-
yisobutylisonitrile SPECT. Nucl. Med. Commun., 14, 42 - 46.
KHALKHALI I, MENA I, JOUANNE E, DIGGLES L, VENEGAS R,
BLOCK J, ALLE K AND KLEIN S. (1994). Prone scintimammo-
graphy in patients with suspicions of breast cancer. J. Am. Coll.
Surg., 178, 491 - 497.
KOSTAKOGLU L, ABDEL-DAYEN H, BRIEN J, CASTELLINO R,
HILTON S AND LARSON S. (1992). Assessment of intermediate
grade lymphoma (IGL) with a new tumour agent, Tc-99m
sestamibi (abstract). Eur. J. Nucl. Med., 19, 579.
MALPAS JS, TIROVOLA EB, BIASSONI L, KALEVA N, KOUYKIN V
AND BRITTON KE. (1995). Myeloma imaging with Tc-99m MIBI.
Proc. 5th International Workshop on Multiple Myeloma, La
Baule, France, 10- 13 September 1995, 3, 120.$20- 99mTc-MIBI in myeloma
EB Tirovola et al
1820
MORETTI JL, CAGLAR M, BOAZIZ C, CAILLAT-VIGNERON N AND
MORERE JF. (1995a). Sequential functional imaging with
technetium-99m hexakis-2-methoxy-isobutylisonitrile and in-
dium-l11 octreotide: can we predict the response to chemother-
apy in small cell lung cancer? Eur. J. Nucl. Med., 22, 177 - 180.
MORETTI JL, CAGLAR M, DURAN-CORDOBES M AND MORERE JF.
(1995b). Can nuclear medicine predict response to chemotherapy?
Eur. J. Nucl. Med., 22, 97 - 100.
MULLER S, GUTH-TOUGELIDES B AND CREUTZIG H. (1987).
Imaging ofmalignant tumours with Tc-99m MIBI (abstract). Eur.
J. Nucl. Med., 28, 562.
MULLER S, REINERS C, PAAS M, GUTH-TOUGELIDES B, BUDACH
V, KONIETZKO N AND ALBERTI W. (1989). Tc-99m MIBI and TI-
201 uptake in bronchial carcinoma (abstract). Eur. J. Nucl. Med.,
30, 845.
PEARCE HL, SAFA AR, BACH NJ, WINTER MA, CIRTAIN MC AND
BECK WT. (1989). Essential features of the P-glycoprotein
pharmacophore as defined by a series of reserpine analogs that
modulate multidrug resistance. Proc. Natl Acad. Sci. USA, 86,
5128 - 5132.
PIWNICA-WORMS D, CHIU ML, BUDDING M, KRONAUGE JF,
KRAMER RA AND CROOP JM. (1993). Functional imaging of
multidrug resistant P-glycoprotein with an organotechnetium
complex. Cancer Res., 53, 1 - 8.
PIWNICA-WORMS D, KRONAUGE JF AND CHIU ML. (1990).
Uptake and retention of Hexakis (2-methoxyisobutyl isonitrile)
Technetium (I) in cultured chick myocardial cells: mitochondrial
and plasma potential dependence. Circulation, 82, 1826 - 1838.
UNLU M, HAZNEDAR R, ATAVCI S, INANIR S AND TARGUT B.
(1995). Detection of bone lesions in multiple myeloma using Tc-
99m MIBI scintigraphy (abstract). Proceedings of the 28th
Congress of the European Association of Nuclear Medicine
(Brussels, 27 August, 1995). Eur. J. Nucl. Med., 22 (suppl.), 739.
WACKERS FJ Th, BERMAN DS, MADDAHI J, WATSON DD, BELLER
GA, STRAUSS HW, BOUCHER CA, PICARD M, HOLMAN BL,
FRIDRICH R, INGLESE E, DELALOYE B, BISCHOF-DELALOYE A,
CAMIN L AND MCKUSICK K. (1989). Technetium-99m hexakis 2-
methoxyisobutyl isonitrile: human biodistribution, dosimetry,
safety and preliminary comparison to thallium-201 for myocar-
dial perfusion imaging. J. Nucl. Med., 30, 301 - 311.
WAHNER H, RYLE R AND POEABONE J. (1980). Scintigraphic
evaluation of the skeleton in multiple myeloma. Mayo clinic
Proc., 55, 739 - 746.
WAXMAN A, SIEMSEN J AND LEVIN AM. (1981). Radiographic and
radionuclide imaging in multiple myeloma: the role of Gallium
scintigraphy (concise communication). J. Nucl. Med., 22, 232 -
236.